This inventor holds 3 USPTO granted patents and 3 published patent applications. Top assignee: Blueprint Medicines Corporation. Active years: 2023-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023-2026
Title: Christopher De Savi: Innovator in Cancer Treatment
Introduction
Christopher De Savi is a notable inventor based in Cambridge, MA (US), recognized for his contributions to the field of cancer treatment. With a total of 2 patents to his name, he has made significant strides in developing innovative therapies.
Latest Patents
His latest patents focus on EGFR inhibitors, which are compounds designed to treat cancer. The present disclosure provides a compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof, useful for treating various types of cancer. This groundbreaking work highlights his commitment to advancing medical science and improving patient outcomes.
Career Highlights
Christopher De Savi is currently associated with Blueprint Medicines Corporation, a company dedicated to delivering targeted therapies for patients with genomically defined cancers. His role at the company allows him to leverage his expertise in developing effective cancer treatments.
Collaborations
Some of his notable coworkers include Natasja Brooijmans and Jason D Brubaker, who contribute to the collaborative environment at Blueprint Medicines Corporation. Their combined efforts enhance the innovative capabilities of the organization.
Conclusion
Christopher De Savi's work in developing EGFR inhibitors exemplifies his dedication to fighting cancer through innovation. His contributions to the field are invaluable and continue to inspire advancements in medical research.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile